You are viewing the site in preview mode

Skip to main content

Table 2 Hazard ratios for premenopausal breast cancer in relation to central/peripheral adiposity, by breast cancer characteristics

From: Central and peripheral adiposity and premenopausal breast cancer risk: a pooled analysis of 440,179 women

Breast cancer characteristics,

Type(a)

Analyses based on waist circumference

Analyses based on hip and waist circumference

 

Waist circumference,

per 10 cm

Waist-to-height ratio,

per 0.1 units

 

Hip circumference,

per 10 cm

Waist-to-hip ratio,

per 0.1 units

 

No. cases

HR (95% CI)

HR (95% CI)

No. cases

HR (95% CI)

HR (95% CI)

Invasiveness

In situ

1224

0.93 (0.85–1.02)

0.82 (0.70–0.95)

1216

1.02 (0.93–1.12)

0.91 (0.83–0.99)

Invasive

5143

1.01 (0.97–1.06)

1.04 (0.97–1.11)

5115

0.99 (0.94–1.04)

1.02 (0.98–1.06)

  

p-het = 0.08

p-het = 0.005

 

p-het = 0.5

p-het = 0.02

ER-status

ER + 

3764

1.03 (0.98–1.08)

1.02 (0.94–1.11)

3746

1.08 (1.01–1.14)

0.98 (0.94–1.03)

ER-

1122

0.97 (0.89–1.06)

1.04 (0.90–1.20)

1114

0.91 (0.83–1.01)

1.03 (0.94–1.12)

  

p-het = 0.25

p-het = 0.84

 

p-het = 0.003

p-het = 0.4

Combined ER and PR status

ER + PR + 

2970

1.03 (0.98–1.09)

1.02 (0.94–1.12)

2958

1.10 (1.03–1.17)

0.98 (0.92–1.03)

ER + PR-

439

0.99 (0.85–1.15)

0.95 (0.74–1.23)

437

1.07 (0.91–1.24)

0.95 (0.82–1.10)

ER-PR + 

185

1.10 (0.90–1.36)

1.57 (1.14–2.15)

185

0.97 (0.79–1.18)

1.10 (0.92–1.31)

ER-PR-

889

0.98 (0.90–1.08)

1.01 (0.86–1.18)

882

0.91 (0.81–1.01)

1.05 (0.95–1.15)

  

p-het = 0.7

p-het = 0.065

 

p-het = 0.019

p-het = 0.35

Breast cancer intrinsic subtype (b)

Luminal A

1472

0.99 (0.91–1.07)

0.94 (0.82–1.07)

1471

1.09 (0.99–1.21)

0.95 (0.87–1.04)

Luminal B-HER2-neg

238

0.95 (0.78–1.16)

0.93 (0.67–1.31)

238

1.10 (0.89–1.36)

0.88 (0.72–1.08)

Luminal B-HER2-pos

383

1.18 (1.03–1.36)

1.46 (1.17–1.84)

383

0.84 (0.71–0.98)

1.29 (1.15–1.45)

HER2-enriched (ER-PR-)

150

1.19 (0.93–1.52)

1.30 (0.86–1.96)

150

1.34 (1.03–1.75)

1.00 (0.78–1.27)

Triple Negative

308

1.03 (0.88–1.20)

1.08 (0.83–1.41)

306

0.94 (0.78–1.13)

1.07 (0.92–1.25)

  

p-het = 0.1

p-het = 0.01

 

p-het = 0.01

p-het < 0.001

  1. BMI, body mass index; CI, confidence interval; ER, oestrogen-receptor; HR, hazard ratio; p-het, P-value for heterogeneity test; PR, progesterone-receptor
  2. (a) Adjusted for study centre, attained age, birth cohort, age at menarche, age at first birth, number of births, time since last birth, adult height and additionally for the main effect of BMI plus an interaction term for BMI with breast cancer subtype (see supplementary methods)
  3. (b) Luminal A-like: ER + PR + HER2-; Luminal B-like, HER2-: ER + PR − HER2- and ER − PR + HER2-; luminal B-like, HER2 + : [ER + and/or PR +] and HER2 + ; HER2-enriched: ER − PR − HER2 + ; and Triple-negative: ER − PR − HER2- as proposed by St Gallen Expert Consensus. [13]
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us